Interactions between CYP2E1 and CYP2B4: effects on affinity for NADPH-cytochrome P450 reductase and substrate

Cesar Kenaan1, Erin V Shea, Hsia-lien Lin

  • 1Chemical Biology Doctoral Program, The University of Michigan, Ann Arbor, Michigan, USA.

Insights

Cytochrome P450 2E1 (CYP2E1) inhibits the activity of Cytochrome P450 2B4 (CYP2B4) by affecting its interaction with cytochrome P450 reductase (CPR). This interaction suggests CYP2E1 can outcompete CYP2B4 for CPR.

Area of Science:

  • Biochemistry
  • Enzymology
  • Pharmacology

Background:

  • Cytochrome P450 (CYP) isoforms can modulate each other's activity.
  • Understanding these interactions is crucial for predicting drug metabolism and toxicity.

Purpose of the Study:

  • To investigate the influence of CYP2E1 on the catalytic activity of CYP2B4.
  • To elucidate the mechanism of CYP2E1-CYP2B4 interaction.

Main Methods:

  • Steady-state enzyme kinetics were used to assess the interaction between CYP2E1 and CYP2B4.
  • Benzphetamine (BNZ) and p-nitrophenol were used as substrates.
  • The role of cytochrome P450 reductase (CPR) was examined.

Main Results:

  • CYP2E1 significantly inhibited CYP2B4-mediated benzphetamine metabolism (Ki = 0.04 µM).
  • CYP2E1 exhibited mixed inhibition of CYP2B4 activity concerning CPR, altering both apparent Km and kcat.
  • CYP2B4 enhanced CYP2E1's affinity for CPR, suggesting competitive binding.

Conclusions:

  • CYP2E1 can inhibit CYP2B4 activity through complex interactions involving CPR.
  • CYP2B4 may enhance CYP2E1's affinity for CPR, potentially leading to CYP2E1 outcompeting CYP2B4 for the reductase.

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...